Non–vitamin K oral anticoagulants (NOACs) are now widely used as alternatives to warfarin
for stroke prevention in atrial fibrillation and management of venous thromboembolism. In …

Background Dabigatran, a direct thrombin inhibitor, is effective for the treatment of venous
thromboembolism and the prevention of stroke and systemic embolism resulting from atrial …

Background: Over the last ten years, a new class of drugs, known as the direct-acting oral
anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy. Like the …

Venous thromboembolism (VTE) is a common complication of cancer and has a significant
impact on morbidity and mortality in patients with malignancies. Low molecular weight …

The prescription of new oral anticoagulants is on the rise. As opposed to vitamin K
antagonists and heparins the new agents have single targets in the coagulation cascade …

Comparison of novel oral anticoagulants versus vitamin K ant... : Current Opinion in
Nephrology and Hypertension Comparison of novel oral anticoagulants versus vitamin K …

Dabigatran etexilate represents a possible improved alternative to warfarin for
anticoagulation in hemodialysis patients with atrial fibrillation (AF). The objective was to …

Significant progress has been made in the development of medications to prevent
thrombosis and platelet aggregation. These drugs target specific components of the …

Context. Severe bleeding associated with dabigatran frequently requires intensive care
management. An antidote is currently unavailable and data reporting the effect of dialysis on …

The use of anticoagulants has become more frequent due to the progressive aging
population and increased thromboembolic events. Consequently, the proportion of …